Showing 1 - 8 of 8
The cost-effectiveness of hormone replacement therapy (HRT) based on a societal perspective is reassessed based on new medical evidence found in the Women's Health Initiative (WHI). Within a model framework using an individual state transition model the cost-effectiveness of 50-60 year old women...
Persistent link: https://www.econbiz.de/10002482555
This paper deals with the question how to model health effects after the cessation of a randomised controlled trial (RCT). Using clinical trial data on severe congestive heart failure patients we illustrate how survival beyond the cessation of a RCT can be predicted based on parametric survival...
Persistent link: https://www.econbiz.de/10001600068
There are few studies investigating the consequences of osteoporotic (low bone density) fractures in terms of costs and health outcomes. The purpose of this Swedish pilot study is to assess the costs and quality of life related to fractures of the hip, spine, wrist and shoulder and further to...
Persistent link: https://www.econbiz.de/10001700726
Persistent link: https://www.econbiz.de/10000978585
Persistent link: https://www.econbiz.de/10000928582
Persistent link: https://www.econbiz.de/10000969942
Persistent link: https://www.econbiz.de/10000987480
Background: The Fracture Intervention Trial (FIT) showed that the bisphosphonate alendronate reduces the risk of fractures in women with low bone mass in the United States. Objective: To estimate the cost-effectiveness (cost per life-year gained and cost per quality-adjusted life-year, QALY,...
Persistent link: https://www.econbiz.de/10001673640